Apyx Medical Corporation

NASDAQ:APYX

Medical - Devices

Healthcare
$2.49 -1.90%

-$0.08 today

Market cap
$104.89M
Beta
1.39
P/E (TTM)
-19.0
EPS (TTM)
-$0.22
52W Low $1.59High $5.08

Volume 0.19M

Average 0.18M

APYX Accounts Payables

Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.

Apyx Medical CorporationNASDAQ: APYX

Accounts Payables · Q1 FY2026 · quarter ended Mar 2026

Accounts payables grows, but more slowly than its trailing trend

Q1 FY2026 accounts payables of $411K (cash outflow) rose 24.2% year over year, behind the +34.1% change in trailing-twelve-month accounts payables. Sequentially, it rose 165.2% from the prior quarter. Over 3 fiscal years it compounded at +74.3% a year.

Context

  • Accounts payables amounted to 0.7% of revenue in FY2025, up 0.5 pp from a year earlier.
  • Accounts payables increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +24.2% toward the trailing-twelve-month pace of +34.1%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$411K+165.2% QoQ
Last fiscal yearDec 2025
$355K+663.5% YoY
LTMMar 2026
$275K+34.1% YoY
Accounts Payables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+24.2%——
1 year+663.5%——
3-year CAGR+74.3%——
5-year CAGR——
10-year CAGR——

Accounts Payables history

USD · from the cash flow

Latest · FY2025
355K USD
Year-over-year change
+663.5%
4-year CAGR
-25.5%

Accounts Payables vs competitors

How APYX compares with its peers on the latest reported figures

  • APYX's LTM Mar 2026 accounts payables of $275K is the 5th largest of the 8 companies compared; the peer median is $83K.
  • Its year-over-year change of +34.1% is the 4th highest of 8, against a peer median of -83.9%.
  • Accounts payables amounts to 0.5% of revenue for APYX, versus a peer median of 3.4%.
APYX Competitors Peer median
Accounts Payables for APYX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RPIDRapid Micro Biosystems, Inc.LTM Mar 2026$2.03M +38.0%+2.5%5.9%
RCELAVITA Medical, Inc.LTM Mar 2026$1.37M -139.9%+113.5%1.9%
XTNTXtant Medical Holdings, Inc.LTM Mar 2026$586K +67.9%—0.5%
PDEXPro-Dex, Inc.LTM Mar 2026$486K -114.6%-55.2%0.7%
APYXApyx Medical CorporationLTM Mar 2026$275K +34.1%+74.3%0.5%
LUCDLucid Diagnostics Inc.LTM Mar 2026$250K +278.6%-15.3%4.9%
SERASera Prognostics, Inc.LTM Mar 2026$83K -83.9%—145.6%
VANIVivani Medical, Inc.LTM Mar 2026$36K -90.9%-51.5%—
Peer median (excluding APYX) $83K-83.9%-15.3%3.4%

Competitors are the stored peer set for APYX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(15.2M)(23.28M)(18.85M)(23.56M)(11.11M)
Depreciation & Amortization903K890K692K599K655K
Deferred Income Tax00000
Stock-Based Compensation5.09M6.7M5.11M4.01M2M
Change in Working Capital(1.84M)(5.22M)5.54M(1.25M)(1.59M)
Accounts Receivables(4.9M)1.92M3.97M(2.04M)(1.32M)
Inventory(2.86M)(5.57M)1.46M2.26M(1.07M)
Accounts Payables1.15M67K25K(63K)355K
Other Working Capital4.76M(1.63M)88K(1.41M)446K
Other Non-Cash Items603K628K2.25M2.15M2.04M
Operating Cash Flow(10.45M)(20.28M)(5.25M)(18.05M)(8M)
Capital Expenditures(723K)(1.01M)(533K)(722K)(1.11M)
Acquisitions (Net)195K07.41M00
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities(195K)0(147K)00
Investing Cash Flow(723K)(1.01M)6.73M(722K)(1.11M)
Debt Repayment(238K)(148K)35.04M(20K)(20K)
Common Stock Issued67K365K2.72M7M9.54M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities195K0(5.59M)(235K)60K
Financing Cash Flow24K217K32.17M6.75M9.58M
Effect of Forex Changes103K395K(191K)113K(466K)
Net Change in Cash(11.05M)(20.68M)33.46M(11.91M)(1K)
Free Cash Flow(11.17M)(21.29M)(5.78M)(18.77M)(9.12M)

Apyx Medical Corporation

NASDAQ:APYX

Intrinsic Alpha fair value

Locked

Current Price

$2.49

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.